Daré Bioscience (Nasdaq:DARE) - Aktienkurs, Nachrichten und Analyse

DARE Aktienübersicht

Daré Bioscience, Inc. ist ein biopharmazeutisches Unternehmen, das Produkte für die Gesundheit von Frauen in den Vereinigten Staaten identifiziert, entwickelt und vermarktet. Mehr Details

DARE grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	5/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	2/6
Dividenden	0/6

Belohnungen

Prognostiziertes Gewinnwachstum 71.37% pro Jahr

Risikoanalyse

Negatives Eigenkapital

Hat keine nennenswerten Einnahmen ($2M)

Hat keine nennenswerte Marktkapitalisierung ($28M)

Die Aktionäre wurden im vergangenen Jahr verwässert

Daré Bioscience, Inc. Wettbewerber

Verrica Pharmaceuticals

NasdaqGM:VRCA

US$40.5m

Nutriband

NasdaqCM:NTRB

US$55.3m

Marinus Pharmaceuticals

NasdaqGM:MRNS

US$17.0m

IGC Pharma

NYSEAM:IGC

US$25.8m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Daré Bioscience
Historische Aktienkurse
Aktueller Aktienkurs	US$3.23
52-Wochen-Hoch	US$7.56
52-Wochen-Tief	US$3.05
Beta	1.34
11 Monat Veränderung	-12.94%
3 Monate Veränderung	-9.01%
1 Jahr Veränderung	-18.90%
33 Jahre Veränderung	-84.79%
5 Jahre Veränderung	-66.16%
Veränderung seit IPO	-95.51%

Aktuelle Nachrichten und Updates

Recent updates

Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms

Oct 17

Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive

Oct 10

Dare Bioscience reports positive progress for cream for female sexual arousal disorder

Aug 29

Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy

Jun 30

Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?

Apr 02

Diving Back Into Daré Bioscience Again

Jan 07

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Nov 26

Daré Bioscience's DARE-BV1 shows positive action in late-stage bacterial vaginosis study

Apr 26

Diving Into Daré Bioscience

Jan 31

Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching

Dec 22

Dare Bioscience EPS misses by $0.06

Nov 12

Aktionärsrenditen

	DARE	US Pharmaceuticals	US Markt
7D	-9.4%	-1.4%	0.3%
1Y	-18.9%	10.8%	31.1%

Rendite im Vergleich zur Industrie: DARE unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 10.8% erzielte.

Rendite vs. Markt: DARE hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 31.1 erzielte.

Preisvolatilität

Is DARE's price volatile compared to industry and market?
DARE volatility
DARE Average Weekly Movement	8.0%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: DARE hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: DAREDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 16% auf 8% zurückgegangen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
n/a	25	Sabrina Johnson	darebioscience.com

Daré Bioscience, Inc. ist ein biopharmazeutisches Unternehmen, das Produkte für die Gesundheit von Frauen in den Vereinigten Staaten identifiziert, entwickelt und vermarktet. Es entwickelt Therapien in den Bereichen Empfängnisverhütung, reproduktive Gesundheit, Menopause, Fruchtbarkeit sowie sexuelle und vaginale Gesundheit. Das Unternehmen bietet XACIATO für die Behandlung von bakterieller Vaginose bei Patientinnen ab 12 Jahren an.

Daré Bioscience, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Daré Bioscience im Vergleich zum Marktanteil des Unternehmens?
DARE grundlegende Statistiken
Marktanteil	US$27.62m
Gewinn(TTM)	-US$3.60m
Umsatz(TTM)	US$1.88m

14.9x

Kurs-Umsatz-Verhältnis

-7.8x

Kurs-Gewinn-Verhältnis

Ist DARE zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
DARE Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$1.88m
Kosten der Einnahmen	US$21.65m
Bruttogewinn	-US$19.76m
Sonstige Ausgaben	-US$16.16m
Umsatz	-US$3.60m

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.42
Bruttomarge	-1,050.56%
Nettogewinnspanne	-191.61%
Schulden/Eigenkapital-Verhältnis	-302.4%

Wie hat sich DARE auf lange Sicht entwickelt?

Historische Performance und Vergleiche

DARE Aktienübersicht

Belohnungen

Risikoanalyse

Daré Bioscience, Inc. Wettbewerber

NasdaqGM:VRCA

US$40.5m

NasdaqCM:NTRB

US$55.3m

NasdaqGM:MRNS

US$17.0m

NYSEAM:IGC

US$25.8m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Daré Bioscience, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Daré Bioscience, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Dare Bioscience, Inc. Announces Publication in Obstetrics & Gynecology of Phase 2B Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

Daré Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $18.08963 million.

Recent updates

Daré Bioscience, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Daré Bioscience, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Daré Bioscience, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Dare Bioscience, Inc. Announces Publication in Obstetrics & Gynecology of Phase 2B Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

Daré Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $18.08963 million.

Daré Bioscience, Inc., Annual General Meeting, Jun 05, 2024

Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer

Daré Bioscience, Inc. Announces Executive Changes

Daré Bioscience's Common Stock to Be Delisted from Nasdaq Unless the Company Timely Requests A Hearing Before the Nasdaq Hearing Panel

Daré Bioscience's Common Stock to Be Delisted from Nasdaq Unless the Company Timely Requests A Hearing Before the Nasdaq Hearing Panel

Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study

Dare Bioscience, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1

Dare Bioscience, Inc. Announces Commencement of Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

New major risk - Revenue and earnings growth

We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate

Daré Bioscience, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Price target decreased by 11% to US$5.33

New major risk - Financial position

New major risk - Revenue size

Daré Bioscience, Inc. Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth

Daré Bioscience Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Dare Bioscience, Inc. Announces Additional Positive Data from Exploratory Phase 2b Response Study of Sildenafil Cream, 3.6% in Women

New minor risk - Profitability

Consensus revenue estimates decrease by 18%

Daré Bioscience, Inc. Provides Update on Activities to Support Commercial Launch of XACIATO

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women

Dare Bioscience, Inc. Announces Positive Topline Data from the Exploratory Phase 2b Response Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Consensus revenue estimates increase by 29%, EPS downgraded

No longer forecast to breakeven

Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?

Price target increased by 13% to US$6.00

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

Daré Bioscience, Inc. Announces Positive Pharmacokinetic Results from the DARE-HRT1 Phase 1 / 2 Study

Forecast to breakeven in 2025

Daré Bioscience Receives Non-Compliance Notice From Nasdaq

Consensus revenue estimates fall by 38%

Consensus forecasts updated

Price target decreased to US$5.33

Daré Bioscience, Inc. Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study

Daré Bioscience Announces Subject Screening for Phase 2B Respond Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

Daré Announces Topline Results of Its Phase 1/2 Clinical Study of Dare-HRT1

Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms

Daré Bioscience, Inc. Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive

Daré Bioscience Announces Interim Analysis of Phase 2B Respond Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Dare Bioscience reports positive progress for cream for female sexual arousal disorder

Consensus revenue estimates increase by 24%

No longer forecast to breakeven

Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy

Daré Bioscience, Inc., Annual General Meeting, Jul 14, 2022

Consensus revenue estimates increase by 11%

Daré Bioscience, Inc., Annual General Meeting, Jun 23, 2022

Price target increased to US$8.25

Forecast to breakeven in 2024

Daré Bioscience, Inc. Initiates Phase 1/2 Clinical Study of DARE-HRT1

Erträge & Einnahmen